Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?

Viruses

Volumn 3, Issue 6, 2011, Pages 750-769

  Nasr, Rihab ^a   Hajj, Hiba El ^a   Kfoury, Youmna ^a   de Thé, Hugues ^b   Hermine, Olivier ^c   Bazarbachi, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Institut Universitaire d'Hématologie   (France)

^c CNRS   (France)

Author keywords

Adultt cell leukemia; Arsenic trioxide; Azt; Htlv i; Interferon; Tax

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; INTERFERON; TAX PROTEIN; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN TARGETING; T CELL LEUKEMIA; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENE PRODUCTS, TAX; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; VIRUS REPLICATION;

HUMAN T-LYMPHOTROPIC VIRUS 1; MUS;

EID: 79959631178     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v3060750     Document Type: Article

References (114)

1. Matsuoka, M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003, 22, 5131-5140.
2. Kaplan, J.E.; Khabbaz, R.F. The epidemiology of human T-lymphotropic virus types I and II. Rev. Med. Virol. 1993, 3, 137-148
3. Nagai, M.; Osame, M. Human T-cell lymphotropic virus type I and neurological diseases. J. Neurovirol. 2003, 9, 228-235.
4. Abbaszadegan, M.R.; Gholamin, M.; Tabatabaee, A.; Farid, R.; Houshmand, M.; Abbaszadegan, M. Prevalence of human T-lymphotropic virus type 1 among blood donors from Mashhad, Iran. J. Clin. Microbiol. 2003, 41, 2593-2595.
5. Hinuma, Y.; Komoda, H.; Chosa, T.; Kondo, T.; Kohalura, M.; Takenaka, T.; Kikichu, M.; Ichimaru, M.; Yunoki, K.; Sato, I.; Matsuo, R.; Takiuchi, Y.; Uchino, H.; Hanaoka, M. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: A nation-wide sero-epidemiologic study. Int. J. Cancer 1982, 29, 631-635.
6. Gessain, A.; Barin, F.; Vernant, J. C.; Gout, O.; Maurs, L.; Calender A., De The, G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, 2, 407-410.
7. Osame, M.; Usuku, K.; Izumo, S.; Ijichi, N.; Amitani, H.; Igata, A.; Matsumoto, M.; Tara, M. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986, 1, 1031-1032.
8. Carvalho, E.M.; Da Fonseca Porto, A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol. 2004, 26, 487-497.
9. Giam, C.Z.; Jeang, K.T. HTLV-1 Tax and adult T-cell leukemia. Front. Biosci. 2007, 12, 1496-1507.
10. Okamoto, T.; Ohno, Y.; Sugane, S.; Watanabe, S.; Shimoyama, M.; Tajima, K.; Miwa, M.; Shimotohno, K. Multi-step carcinogenesis model for adult T-cell leukemia. Jpn. J. Canc. Res. 1989, 80, 191-195.
11. Yoshida, M.; Seiki, M.; Yamaguchi, K.; Takatsuki, K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc. Natl. Acad. Sci. U. S. A. 1984, 81, 2534-2537.
12. Hisada, M.; Okayama, A.; Shioiri, S.; Spiegelman, D.L.; Stuver, S.O.; Mueller, N.E. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood 1998, 92, 3557-3561.
13. Okayama, A.; Tachibana, N.; Ishihara, S.; Nagatomo, Y.; Murai, K.; Okamoto, M.; Shima, T.; Sagawa, K.; Tsubouchi, H.; Stuver, S. et al. Increased expression of interleukin-2 receptor alpha on peripheral blood mononuclear cells in HTLV-I tax/rex mRNA-positive asymptomatic carriers. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1997, 15, 70-75.
14. Slamon, D.J.; Shimotohno, K.; Cline, M.J.; Golde, D.W.; Chen, I.S. Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science 1984, 226, 61-65.
15. Gaudray, G.; Gachon, F.; Basbous, J.; Biard-Piechaczyk, M.; Devaux, C.; Mesnard, J. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J. Virol. 2002, 76, 12813-12822.
16. Kannian, P.; Green, P.L. Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis. Viruses 2010, 2, 2037-2077.
17. Journo, C.; Douceron, E.; Mahieux, R. HTLV gene regulation: because size matters, transcription is not enough. Future Microbiol. 2009, 4, 425-440.
18. Manel, N.; Kim, F.J.; Kinet, S.; Taylor, N.; Sitbon, M.; Battini, J.L. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003, 115, 449-459.
19. Ghez, D.; Lepelletier, Y.; Jones, K.S.; Pique, C.; Hermine, O. Current concepts regarding the HTLV-1 receptor complex. Retrovirology 2010, 7, 99.
20. Ghez, D.; Lepelletier, Y.; Lambert, S.; Fourneau, J.M.; Blot, V.; Janvier, S.; Arnulf, B.; van Endert, P.M.; Heveker, N.; Pique, C.; Hermine, O. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J. Virol. 2006, 80, 6844-6854.
21. Takenouchi, N.; Jones, K.S.; Lisinski, I.; Fugo, K.; Yao, K.; Cushman, S.W.; Ruscetti, F.W.; Jacobson, S. GLUT1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1. J. Virol. 2007, 81, 1506-1510.
22. Lambert, S.; Bouttier, M.; Vassy, R.; Seigneuret, M.; Petrow-Sadowski, C.; Janvier, S.; Heveker, N.; Ruscetti, F.W.; Perret, G.; Jones, K.S.; Pique, C. HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165. Blood 2009, 113, 5176-5185.
23. Sibon, D.; Gabet, A.S.; Zandecki, M.; Pinatel, C.; Thête, J.; Delfau-Larue, M.H.; Rabaaoui, S.; Gessain, A.; Gout, O.; Jacobson, S.; Mortreux, F.; Wattel, E. HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death. J. Clin. Invest. 2006, 116, 974-983.
24. Zane, L.; Sibon, D.; Jeannin, L.; Zandecki, M.; Delfau-Larue, M.H.; Gessain, A.; Gout, O.; Pinatel, C.; Lançon, A.; Mortreux, F.; Wattel, E. Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo. Retrovirology 2010, 11, 7-17.
25. Franchini, G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood 1995, 86, 3619-3639.
26. Gatza, M.L.; Watt. J.C. Marriott, S.J. Cellular Transformation by the HTLV-I Tax Protein, a Jack-of-All-Trades. Oncogene 2003, 22, 5141-5149.
27. Kfoury, Y.; Nasr, R.; Hermine, O.; de Thé, H.; Bazarbachi, A. Proapoptotic regimes for HTLV-I-transformed cells: Targeting Tax and the NF-kappaB pathway. Cell Death Differ. 2005, 12, 871-877.
28. Sun, S.C.; Elwood, J.; Béraud, C.; Greene, W.C. Human T-cell leukemia virus type I Tax activation of NF-kappa B/Rel involves phosphorylation and degradation of I kappa B alpha and RelA (p65)-mediated induction of the c-rel gene. Mol. Cell Biol. 1994, 14, 7377-7384.
29. Good, L.; Sun, S.C. Persistent activation of NF-kappa B/Rel by human T-cell leukemia virus type 1 tax involves degradation of I kappa B beta. J. Virol. 1996, 70, 2730-2735.
30. Yin, M.J.; Christerson, L.B.; Yamamoto, Y.; Kwak, Y.T.; Xu, S.; Mercurio, F.; Barbosa, M.; Cobb, M.H.; Gaynor, R.B. HTLV-I Tax protein binds to MEKK1 to stimulate IkappaB kinase activity and NF-kappaB activation. Cell 1998, 93, 875-884.
31. Uhlik, M.; Good, L.; Xiao, G.; Harhaj, E.W.; Zandi, E.; Karin, M.; Sun, S.C. NF-kappaB-inducing kinase and IkappaB kinase participate in human T-cell leukemia virus I Tax-mediated NF-kappaB activation. J. Biol. Chem. 1998, 273, 21132-21136.
32. Journo, C.; Filipe, J.; About, F.; Chevalier, S.A.; Brady, J.N.; Afonso, P.V.; Flynn, D.; Tangy, F.; Israël, A.; Vidalain, P.O.; Weil, R.; Mahieux, R. NRP/Optineurin Cooperates with TAX1BP1 to Potentiate the Activation of NF-κB by Human T-Lymphotropic Virus Type 1 Tax Protein. PLoS Pathog. 2009, 5, e1000521.
33. Xiao, G.; Cvijic, M.E.; Fong, A.; Harhaj, E.W.; Uhlik, M.T.; Waterfield, M.; Sun, S.C. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J. 2001, 20, 6805-6815.
34. Zhao, L.J.; Giam, C.Z. Human T-cell lymphotropic virus type I (HTLV-I) transcriptional activator, Tax, enhances CREB binding to HTLV-I 21 base-pair repeats by protein-protein interaction. Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 7070-7074.
35. Suzuki, T.; Fujisawa, J.I.; Toita, M.; Yoshida, M. The trans-activator tax of human T-cell leukemia virus type 1 (HTLV-1) interacts with cAMP-responsive element (CRE) binding and CRE modulator proteins that bind to the 21-base-pair enhancer of HTLV-1. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 610-614.
36. Fujii, M.; Tsuchiya, H.; Chuhjo, T.; Akizawa, T.; Seiki, M: Interaction of HTLV-I Taxl with p67SRF causes the aberrant induction of cellular immediate early genes through CArG boxes. Gene. Dev. 1992, 6, 2066-2076.
37. Fujii, M.; Iwai, K.; OIie, M.; Fukushi, M.; Yamamoto, N.; Kannagi, M.; Mori, N. Activation of oncogenic transcription factor AP-1 in T cells infected with the human T-cell leukemia virus type 1. AIDS Res. Hum. Retrovir. 2000, 16, 1603-1606.
38. Kfoury, Y.; Setterblad, N.; El-Sabban, M.; Zamborlini, A.; Dassouki, Z.; El Hajj, H.; Hermine, O.; Pique, C.; de Thé, H.; Saïb, A.; Bazarbachi, A. Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome. Blood 2011, 117, 190-199.
39. Kfoury, Y.; Nasr, R.; Favre-Bonvin, A.; El-Sabban, M.; Renault, N.; Giron, M.L.; Setterblad, N.; Hajj, H.E.; Chiari, E.; Mikati, A.G.; Hermine, O.; Saib, A.; de Thé, H.; Pique, C.; Bazarbachi, A. Ubiquitylated Tax targets and binds the IKK signalosome at the centrosome. Oncogene 2008, 27, 1665-1676.
40. Nasr, R.; Chiari, E.; El-Sabban, M.; Mahieux, R.; Kfoury, Y.; Abdulhay, M.; Yazbeck, V.; Hermine, O.; de Thé, H.; Pique, C.; Bazarbachi, A. Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-kappaB activation. Blood 2006, 107, 4021-4029.
41. Jeang, K.T.; Widen, S.G.; Semmes, O.J., 4th; Wilson, S.H. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990, 247, 1082-1084.
42. Kibler, K.V.; Jeang, K.T. CREB/ATF-dependent repression of cyclin a by human T-cell leukemia virus type 1 Tax protein. J. Virol. 2001, 75, 2161-2173.
43. Arnulf, B.; Villemain, A.; Nicot, C.; Mordelet, E.; Charneau, P.; Kersual, J. Zermati,Y. Mauviel, A. Bazarbachi, A. Hermine, O. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood 2002, 100, 4129-4138.
44. Nicot, C.; Mahieux, R.; Takemoto, S.; Franchini, G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 2000, 96, 275-281.
45. Pise-Masison, C.A.; Choi, K.S.; Radonovich, M.; Dittmer, J.; Kim, S.J.; Brady, J.N. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J. Virol. 1998, 72, 1165-1170.
46. Suzuki, T.; Yoshida, M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16Ink4a and counteracts its inhibitory activity to CDK4. Leukemia 1997, 11, 14-16.
47. Afonso PV, Zamborlini A, Saab A, Mahieux R. Centrosome and retroviruses: the dangerous liaisons. Retrovirology 2007, 14, 4, 27.
48. Jeang, K.T. Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction? Oncotarget 2010, 1, 453-456.
49. Matsumoto, K.; Shibata, H.; Fujisawa, J.I.; Inoue, H.; Hakura, A.; Tsukahara, T.; Fujii, M. Human T-cell leukemia virus type 1 Tax protein transforms rat fibroblasts via two distinct pathways. J. Virol. 1997, 71, 4445-4451.
50. Grassmann, R.; Berchtold, S.; Radant, I.; Alt, M.; Fleckenstein, B.; Sodroski, J.G.; Haseltine, W.A.; Ramstedt, U. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J. Virol. 1992, 66, 4570-4575.
51. Hasegawa, H.; Sawa, H.; Lewis, M.J.; Orba, Y.; Sheehy, N.; Yamamoto, Y.; Ichinohe, T.; Tsunetsugu-Yokota, Y.; Katano, H.; Takahashi, H.; Matsuda, J.; Sata, T.; Kurata, T.; Nagashima, K.; Hall, W.W. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat. Med. 2006, 12, 466-472.
52. Banerjee, P.; Tripp, A.; Lairmore, M.D.; Crawford, L.; Sieburg, M.; Ramos, J.C.; Harrington, W., Jr.; Beilke, M.A.; Feuer, G. Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. Blood 2010, 115, 2640-2648.
53. Tamiya, S.; Matsuoka, M.; Etoh, K.; Watanabe, T.; Kamihira, S.; Yamaguchi, K.; Takatsuki, K. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1996, 88, 3065-3073.
54. Furukawa, Y.; Kubota, R.; Tara, M.; Izumo, S.; Osame, M. Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood 2001, 97, 987-993.
55. Koiwa, T.; Hamano-Usami, A.; Ishida, T.; Okayama, A.; Yamaguchi, K.; Kamihira, S.; Watanabe, T. 5'-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. J. Virol. 2002, 76, 9389-9397.
56. Takeda, S.; Maeda, M.; Morikawa, S.; Taniguchi, Y.; Yasunaga, J.; Nosaka, K.; Tanaka, Y.; Matsuoka, M. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int. J. Cancer. 2004, 109, 559-567.
57. Basbous, J.; Arpin, C.; Gaudray, G.; Piechaczyk, M.; Devaux, C.; Mesnard, J.M. The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J. Biol. Chem. 2003, 278, 43620-43627.
58. Taylor, J.M.; Ghorbel, S.; Nicot, C. Genome wide analysis of human genes transcriptionally and post-transcriptionally regulated by the HTLV-I protein p30. BMC Genomics 2009, 10, 311.
59. Datta A, Silverman L, Phipps AJ, Hiraragi H, Ratner L, Lairmore MD: Human T-lymphotropic virus type-1 p30 alters cell cycle G2 regulation of T lymphocytes to enhance cell survival. Retrovirology 2007, 4, 49.
60. Liu, M.; Yang, L.; Zhang, L.; Liu, B.; Merling, R.; Xia, Z.; Giam, CZ. Human T-cell leukemia virus type 1 infection leads to arrest in the G1 phase of the cell cycle. J. Virol. 2008, 82, 8442-8455.
61. Jones, K.S.; Petrow-Sadowski, C.; Huang, Y.K.; Bertolette, D.C.; Ruscetti, F.W. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat. Med. 2008, 14, 429-36.
62. El Hajj, H.; El-Sabban, M.; Hasegawa, H.; Zaatari, G.; Ablain, J.; Saab, S.T.; Janin, A.; Mahfouz, R.; Nasr, R.; Kfoury, Y.; Nicot, C.; Hermine, O.; Hall, W.; de Thé, H.; Bazarbachi, A. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J. Exp. Med. 2010, 207, 2785-2792.
63. Kinpara S, Hasegawa A, Utsunomiya A, Nishitsuji H, Furukawa H, Masuda T, Kannagi M. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J. Virol. 2009, 83, 5101-5108.
64. Chlichlia, K.; Khazaie, K. HTLV-1 Tax: Linking transformation, DNA damage and apoptotic T-cell death. Chem. Biol. Interact. 2010, 188, 359-365.
65. Kuo, Y.L.; Giam, C.Z. Activation of the anaphase promoting complex by HTLV-1 tax leads to senescence. EMBO J. 2006, 25, 1741-1752.
66. Hanon, E.; Stinchcombe, J.C.; Saito, M.; Asquith, B.E.; Taylor, G.P.; Tanaka, Y.; Weber, J.N.; Griffiths, G.M.; Bangham, C.R. Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity 2000, 13, 657-664.
67. Asquith, B.; Zhang, Y.; Mosley, A.J.; de Lara, C.M.; Wallace, D.L.; Worth, A.; Kaftantzi, L.; Meekings, K.; Griffin, G.E.; Tanaka, Y.; Tough, D.F.; Beverley, P.C.; Taylor, G.P.; Macallan, D.C.; Bangham, C.R. In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 8035-8040.
68. Satou, Y.; Yasunaga, J.; Zhao, T.; Yoshida, M.; Miyazato, P.; Takai, K.; Shimizu, K.; Ohshima, K.; Green, P.L.; Ohkura, N.; Yamaguchi, T.; Ono, M.; Sakaguchi, S.; Matsuoka, M. HTLV-1 bZIP Factor Induces T-Cell Lymphoma and Systemic Inflammation in vivo. PLoS Pathog. 2011, 7, e1001274.
69. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br. J. Haematol. 1991, 79, 428-437.
70. Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, Yamada Y, Kamihira S, Ikeda S, Miyazaki Y, Tomonaga M, Tsukasaki K. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010, 115, 4337-4343.
71. Bazarbachi, A.; Ghez, D.; Lepelletier, Y.; Nasr, R.; de Thé, H.; El-Sabban, M.E.; Hermine, O. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004, 5, 664-672.
72. Bazarbachi, A, Hermine, O. Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives. Virus Res. 2001, 78, 79-92.
73. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br. J. Haematol. 2001, 113, 375-382.
74. Tsukasaki, K.; Hermine, O.; Bazarbachi, A.; Ratner, L.; Ramos, J.C.; Harrington, W. Jr.; O'Mahony, D.; Janik, J.E.; Bittencourt, A.L, Taylor, G.P. Yamaguchi, K. Utsunomiya, A. Tobinai, K. Watanabe, T. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J. Clin. Oncol. 2009, 27, 453-459.
75. Hermine, O.; Bouscary, D.; Gessain, A.; Turlure, P.; Leblond, V.; Franck, N.; Buzyn-Veil, A.; Rio, B.; Macintyre, E.; Dreyfus, F., Bazarbachi, A. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med. 1995, 332, 1749-1751.
76. Gill, P.S.; Harrington, W. Jr., Kaplan, M.H.; Ribeiro, R.C.; Bennett, J.M.; Liebman, H.A.; Bernstein-Singer, M.; Espina, B.M.; Cabral, L.; Allen, S. et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med. 1995, 332, 1744-1748.
77. Bazarbachi, A.; Hermine, O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 13, S186-S190.
78. White, J.D.; Wharfe, G.; Stewart, D.M.; Maher, V.E.; Eicher, D.; Herring, B.; Derby, M.; Jackson-Booth, P.G.; Marshall, M.; Lucy, D.; Jain, A.; Cranston, B.; Hanchard, B.; Lee, C.C.; Top, L.E.; Fleisher, T.A.; Nelson, D.L.; Waldmann, T.A. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk. Lymphoma 2001, 40, 287-294.
79. Matutes, E.; Taylor, G.P.; Cavenagh, J.; Pagliuca, A.; Bareford, D.; Domingo, A.; Hamblin, M.; Kelsey, S.; Mir, N.; Reilly, J.T. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br. J. Haematol. 2001, 113, 779-784.
80. Hermine, O.; Allard, I.; Lévy, V.; Arnulf, B.; Gessain, A.; Bazarbachi, A.; French ATL therapy group. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol. J. 2002, 3, 276-282.
81. Kchour, G.; Makhoul, N.J.; Mahmoudi, M.; Kooshyar, M.M.; Shirdel, A.; Rastin, M.; Rafatpanah, H.; Tarhini, M.; Zalloua, P.A.; Hermine, O.; Farid, R.; Bazarbachi, A. Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk. Lymphoma 2007, 48, 330-336.
82. Ratner, L.; Harrington, W.; Feng, X.; Grant, C.; Jacobson, S.; Noy, A.; Sparano, J.; Lee, J.; Ambinder, R.; Campbell, N.; Lairmore, M.; AIDS Malignancy Consortium. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS ONE 2009, 4, e4420.
83. Besson, C.; Panelatti, G.; Delaunay, C.; Gonin, C.; Brebion, A.; Hermine, O.; Plumelle, Y. Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leuk. Lymphoma 2002, 43, 2275-2279.
84. Bazarbachi, A.; Plumelle, Y.; Carlos Ramos, J.; Tortevoye, P.; Otrock, Z.; Taylor, G.; Gessain, A.; Harrington, W.; Panelatti, G.; Hermine, O. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 2010, 28, 4177-4183.
85. Ishitsuka, K.; Katsuya, H.; Toyota, T.; Ishizu, M.; Kunami, N.; Fujita, M.; Sasaki, H.; Takamatsu, Y.; Uchiyama, M.; Fujikane, H.; Ogata, K.; Hara, S.; Tamura, K. Interferon-α and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: Case reports of Japanese patients. Int. J. Hematol. 2010, 92, 762-764.
86. Fischl, M.A. Richman, D.D. Grieco, M.H. Gottlieb, M.S. Volberding, P.A. Laskin, O.L. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 1987, 317, 185-191.
87. Goodbourn, S.; Didcock, L.; Randall, R.E. Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 2000, 81, 2341-2364.
88. Colisson R, Barblu L, Gras C, Raynaud F, Hadj-Slimane R, Pique C, Hermine O, Lepelletier Y, Herbeuval JP. Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. Blood 2010, 115, 2177-2185.
89. Isono, T.; Ogawa, K.; Seto, A. Antiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits. Leuk. Res. 1990, 14, 841-847.
90. Macchi, B.; Faraoni, I.; Zhang, J.; Grelli, S.; Favalli, C.; Mastino, A.; Bonmassar, E. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J. Gen. Virol. 1997, 5, 1007-1016.
91. Afonso, P.V.; Mekaouche, M.; Mortreux, F.; Toulza, F.; Moriceau, A.; Wattel, E.; Gessain, A.; Bangham, C.R.; Dubreuil, G.; Plumelle, Y.; Hermine, O.; Estaquier, J.; Mahieux, R. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood 2010, 116, 3802-3808.
92. Feng, X.; Heyden, N.V.; Ratner, L. Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J. Virol. 2003, 77, 13389-13395.
93. Daenke, S.; Kermode, A.G.; Hall, S.E.; Taylor, G.; Weber, J.; Nightingale, S.; Bangham, C.R. High activated and memory cytotoxic T-cell responses to HTLV-1 in healthy carriers and patients with tropical spastic paraparesis. Virology 1996, 217, 139-146.
94. Oliere S, Hernandez E, Lezin A, Arguello M, Douville R, Nguyen TL, Olindo S, Panelatti G, Kazanji M, Wilkinson P, Sekaly RP, Cesaire R, Hiscott J. HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog. 2010, 6, e1001177.
95. Tosi, P.; Visani, G.; Ottaviani, E.; Gamberi, B.; Cenacchi, A.; Tura, S. Synergistic cytotoxicity of AZT plus alpha and gamma interferon in chronic myeloid leukemia cell line K562. Eur. J. Haematol. 1993, 51, 209-213.
96. Bazarbachi, A.; Nasr, R.; El-Sabban, M.E.; Mahé, A.; Mahieux, R.; Gessain, A.; Darwiche, N.; Dbaibo, G.; Kersual, J.; Zermati, Y.; Dianoux, L.; Chelbi-Alix, M.K.; de Thé, H.; Hermine, O. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 2000, 14, 716-721.
97. Datta, A.; Bellon, M.; Sinha-Datta, U.; Bazarbachi, A.; Lepelletier, Y.; Canioni, D.; Waldmann, T.A.; Hermine, O.; Nicot, C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006, 108, 1021-1029.
98. El Hajj, H.; Hermine, O.; de Thé, H.; Bazarbachi, A. American University of Beirut, Beirut, Lebanon; Hôpital Necker-Enfants Malades, Paris, France; INSERM, Université Paris Diderot U 7212, Unité 944, Paris, France. The combination AZT/IFN is not effective in Tax-transgenic murine ATL. Unpublished work, 2010.
99. Herishanu, Y.; Pérez-Galán, P.; Liu, D.; Biancotto, A.; Pittaluga, S.; Vire, B.; Gibellini, F.; Njuguna, N.; Lee, E.; Stennett, L.; Raghavachari, N.; Liu, P.; McCoy, J.P.; Raffeld, M.; Stetler-Stevenson, M.; Yuan, C.; Sherry, R.; Arthur, D.C.; Maric, I.; White, T.; Marti, G.E.; Munson, P.; Wilson, W.H.; Wiestner, A. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117, 563-574.
100. Nasr, R.; Lallemand-Breitenbach, V.; Zhu, J.; Guillemin, M.C.; de Thé, H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin. Cancer Res. 2009, 15, 6321-6326.
101. Nasr, R.; Guillemin, M.C.; Ferhi, O.; Soilihi, H.; Peres, L.; Berthier, C.; Rousselot, P.; Robledo-Sarmiento, M.; Lallemand-Breitenbach, V.; Gourmel, B.; Vitoux, D.; Pandolfi, P.P.; Rochette-Egly, C.; Zhu, J.; de Thé, H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 2008, 14, 1333-1342.
102. Bazarbachi, A.; El-Sabban, M.E.; Nasr, R.; Quignon, F.; Awaraji, C.; Kersual, J.; Dianoux, L.; Zermati, Y.; Haidar, J.H.; Hermine, O.; de Thé, H. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999, 93, 278-283.
103. Mahieux, R.; Pise-Masison, C.; Gessain, A.; Brady, J.N.; Olivier, R.; Perret, E.; Misteli, T.; Nicot, C. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001, 98, 3762-3769.
104. El-Sabban, M.E.; Nasr, R.; Dbaibo, G.; Hermine, O.; Abboushi, N.; Quignon, F.; Ameisen, J.C.; Bex, F.; de Thé, H.; Bazarbachi, A. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000, 96, 2849-2855.
105. Nasr, R.; Rosenwald, A., El-Sabban, M.E.; Arnulf, B.; Zalloua, P.; Lepelletier, Y.; Bex, F.; Hermine, O.; Staudt, L.; de Thé, H.; Bazarbachi, A. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003, 101, 4576-4582.
106. Hermine, O.; Dombret, H.; Poupon, J.; Arnulf, B.; Lefrère, F.; Rousselot, P.; Damaj, G.; Delarue, R.; Fermand, J.P.; Brouet, J.C.; Degos, L.; Varet, B.; de Thé, H.; Bazarbachi, A. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol. J. 2004, 5, 130-134.
107. Ishitsuka, K.; Suzumiya, J.; Aoki, M.; Ogata, K.; Hara, S.; Tamura, K. Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica 2007, 92, 719-720.
108. Heraud, J.M.; Mortreux, F.; Merien, F.; Contamin, H.; Mahieux, R.; Pouliquen, J.F.; Wattel, E.; Gessain, A.; de Thé, H.; Bazarbachi, A.; Hermine, O.; Kazanji, M. The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys (Saimiri sciureus). Antivir. Res. 2006, 70, 132-139.
109. Kchour, G.; Tarhini, M.; Kooshyar, M.M.; El Hajj, H.; Wattel, E.; Mahmoudi, M.; Hatoum, H.; Rahimi, H.; Maleki, M.; Rafatpanah, H.; Rezaee, S.A.; Yazdi, M.T.; Shirdel, A.; de Thé, H.; Hermine, O.; Farid, R.; Bazarbachi, A. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113, 6528-6532.
110. Nasr, R.; El-Sabban, M.E.; Karam, J.A.; Dbaibo, G.; Kfoury, Y.; Arnulf, B.; Lepelletier, Y.; Bex, F.; de Thé, H.; Hermine, O.; Bazarbachi, A. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 2005, 24, 419-430.
111. Bangham, C.R. The immune response to HTLV-I. Curr. Opin. Immunol. 2000, 4, 397-402.
112. Akimoto, M.; Kozako, T.; Sawada, T.; Matsushita, K.; Ozaki, A.; Hamada, H.; Kawada, H.; Yoshimitsu, M.; Tokunaga, M.; Haraguchi, K.; Uozumi, K.; Arima, N.; Tei, C. Anti-HTLV-1 tax antibody and tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-1 proviral load in asymptomatic carriers. J. Med. Virol. 2007, 79, 977-986.
113. Hanon, E.; Hall, S.; Taylor, G.P.; Saito, M.; Davis, R.; Tanaka, Y.; Usuku, K.; Osame, M.; Weber, J.N.; Bangham, C.R. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000, 95, 1386-1392.
114. Suarez, F.; Marcais, A.; Ghez, D.; Delarue, R.; Deau-Fischer, B.; Aoun, C.; Sicre de Fontbrune, F.; Ysebaert, L.; Asnafi, V.; Canioni, D.; Bazarbachi, A.; Hermine, O. Arsenic Trioxyde in the treatment of HTLV1 associated ATLL. Retrovirology 2011, 8, A59.